

# Immunomic Therapeutics Receives Notice of Issuance for Chimeric Vaccines Patent

/EINPresswire.com/ FOR IMMEDIATE RELEASE

Hershey, PA, February 22nd, 2013 – Immunomic Therapeutics, Inc., (“ITI”) a privately-held biotechnology company announced that the U.S. Patent and Trademark Office issued US Patent No. 8,318,173, for the application titled “Chimeric Vaccines.” This patent extends the patent protection for [LAMP-Vax™](#) vaccines through at least April, 2022. The issued claims protect the core design and technology utilized in the Company’s LAMP-based DNA vaccine vectors. This technology is being utilized in the Company’s lead product, JRC-LAMP-vax and in several other vaccines currently in development. This issuance rounds out ITI’s worldwide Chimeric Vaccine patent portfolio: the patent has also issued in Japan, Australia and is in the country phase in Europe.

ITI’s VP of R&D, Dr. Teri Heiland, said, “This issued U.S. patent demonstrates the value of the discovery of the LAMP DNA vaccine platform and represents a significant step in strengthening our intellectual property portfolio.” CEO, Bill Hearl, Ph.D., offered, “This patent protects ITI’s investment in the LAMP Technology platform. As we develop vaccines using this technology, we can have confidence that we have a strong position for our intellectual property. Work with LAMP vaccines in animal models and in human clinical studies suggests that we will be able to develop next generation vaccines that will have a very positive impact on human health.”

The Chimeric Vaccines invention by Johns Hopkins Distinguished Professor, Dr. J. Thomas August, describes a cytoplasmic domain for targeting and/or trafficking a chimeric protein to the MHC-II compartment in the cell, promoting enhanced immune response. [Nucleic acid vaccines](#) utilizing a signaling/trafficking domain can be used to modulate or enhance an immune response against any kind of antigen. LAMP vaccines have been broadly applied to infectious disease, cancer and allergy.

Immunomic Therapeutics is currently implementing LAMP Technology in the clinic with an investigational allergy vaccine for the treatment of allergy to Japanese red cedar pollen. ITI has completed enrollment of an open label, Phase I, clinical study designed to establish the safety of the LAMP-Vax vaccine platform. The study, being conducted in Honolulu, HI, is expected to be completed early in 2013.

About Immunomic Therapeutics

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company

headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on its patented LAMP™ Technology platform. LAMP-Vax™ vaccine technology has the potential to significantly increase the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy and infectious diseases. For more information about ITI and LAMP Technology please visit [www.immunomix.com](http://www.immunomix.com).

CONTACT:

Dr. Bill Hearl, President / CEO

Phone: 1-717-327-1919

Immunomix @ gmail.com

Immunomic Therapeutics, Inc.

1214 Research Boulevard, Suite 201, Hershey, PA 17036 E-mail: [info@immunomix.com](mailto:info@immunomix.com)

Web: [www.immunomix.com](http://www.immunomix.com)

Press Release CHIMERA ISSUANCE

Issued 02/22/2013

---

This press release can be viewed online at: <https://www.einpresswire.com/article/138415204>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.